ABSTRACT
H
epatitis b virus (hbv) infection is sometimes challenging to manage because the disease has several stages and many clinical scenarios. HBV-infected patients are a very heterogeneous group, and we cannot apply a single management approach to all.
An understanding of the natural history of HBV infection and its diagnosis, which we reviewed in last month's issue of this Journal 1 (available online at www.ccjm.org/ content/75/12/881), is critical to understanding how to manage HBV infection.
In this article, we will review the principles of HBV management in adults, including those on immunosuppressant therapy and pregnant women, and guidelines for HBV vaccination.
workup for HBV INfECTIoN ■
Once the diagnosis of HBV infection is made, 1 a full management strategy should be formulated, as outlined below.
History
When and how did the patient acquire HBV? This information is important to know when making treatment decisions. For example, most acute, adult-onset cases (eg, acquired recently via sexual contact or parenteral drug abuse) resolve spontaneously within a few months, whereas most chronic cases (defined as being positive for HBV surface antigen for more than 6 months) were acquired at birth or in early childhood. Therefore, we should try to determine if the patient's mother, siblings, household contacts, and sexual partners are positive for HBV surface antigen or have risk factors for HBV infection 
Does the patient have risk factors for other infections? Especially look for risk factors for human immunodeficiency virus (HIV) infection (eg, intravenous drug users and men having sex with men) and hepatitis D virus (intravenous drug users and patients from countries where hepatitis D virus infection is common, particularly Eastern Europe, Mediterranean countries, and the Amazon basin).
Does the patient have other modifiable risk factors for progressive liver disease, particularly alcohol abuse and obesity? Does the patient have symptoms or signs of cirrhosis or hepatocellular carcinoma? Symptoms and signs that involve multiple systems could be extrahepatic manifestations of HBV infection, such as polyarteritis nodosa, which causes abdominal pain, arthralgia, hypertension, and asymmetric polyneuropathy.
Baseline laboratory evaluation
At baseline we should obtain a complete blood count, blood urea nitrogen level, serum creatinine level, liver profile, prothrombin time, urinalysis, and HBV serologic markers. In addition, HBV DNA can be detected in the serum at levels as low as 60 IU/mL, and it should be measured in the initial evaluation to establish a baseline before starting antiviral therapy in patients with chronic HBV infection and subsequently to monitor the response.
All patients with chronic HBV infection should also be tested for serologic markers of hepatitis A and hepatitis C; patients at risk of HIV and hepatitis D should also be tested for these diseases.
Not all patients need liver biopsy
Liver biopsy is the most accurate tool for staging the degree of HBV-related hepatic fibrosis in patients who have no obvious clinical manifestations of cirrhosis.
Not all patients with HBV infection need a biopsy, however. In patients with acute HBV infection, liver biopsy has no benefit except if concomitant pathology (eg, iron overload, nonalcoholic steatohepatitis, or alcoholic steatohepatitis) is suspected. In patients with chronic hepatitis B, liver biopsy is helpful when the viral load alone does not provide sufficient guidance for treatment, eg, when the viral load is less than 2 × 10 4 IU/mL in a patient positive for hepatitis e antigen or less than 2 × 10 3 IU/mL in a patient negative for hepatitis e antigen. (The presence of e antigen is a marker of HBV replication and infectivity.
1 ) Biopsy should also be considered in those who have been infected a long time (eg, more than 10 years), because they may have occult cirrhosis, and if they do they may need to undergo antiviral treatment, endoscopy to look for varices, and surveillance for liver cancer.
In some situations it is easy to decide whether antiviral therapy is indicated without resorting to liver biopsy.
We would treat: A patient positive for HBV e antigen for • more than 6 months, whose HBV DNA level is higher than 2 × 10 4 IU/mL and whose alanine aminotransferase (ALT) level is high A patient with HBV for more than 6 • months who is negative for e antigen and who has an HBV DNA level higher than 2 × 10 3 IU/mL and elevated ALT A patient with compensated HBV cirrho-• sis and an HBV DNA level higher than 2 × 10 3 IU/mL A patient with HBV cirrhosis with decom-• pensation and any detectable HBV DNA. We would not treat: An HBV carrier with a normal ALT level • and an HBV DNA level that is lower than 2 × 10 4 IU/mL or undetectable. If a patient does not fit into one of these categories but has HBV DNA, a liver biopsy showing significant necroinflammation or fibrosis would be an indication for treatment.
In HBV, we cannot apply a single management approach to all ELGOUHARI AND COLLEAGUES
ANTIVIrAL THErApY ■
Below, we summarize the main principles of anti-HBV therapy, emphasizing whether to treat and with which agent. Treatment of HBV infection in patients who are also infected with HIV or hepatitis C virus and in those with resistant or refractory hepatitis B is not within the scope of this article.
Acute infection rarely needs treatment
Acute, adult-acquired HBV infection is selflimited in most cases, 1 and antiviral therapy is not routinely indicated.
In the rare cases of acute liver failure related to acute HBV infection, use of a nucleoside or nucleotide analogue reverse transcriptase inhibitor (nucleoside/nucleotide analogues) has been recommended, although no properly designed studies have been done. 2, 3 This recommendation is based on anecdotal experience, the relative safety of the antiviral agents, the serious nature of acute liver failure, and the possible need for emergency liver transplantation that requires prophylaxis against recurrence.
The nucleoside/nucleotide analogues that have been recommended in acute liver failure are lamivudine (Epivir), telbivudine (Tyzeka), and entecavir (Baraclude)-but not adefovir (Hepsera), which has a slow action and potential nephrotoxicity. Interferon drugs are contraindicated because they frequently cause side effects and can worsen hepatitis. 4 Patients with acute liver failure should be referred promptly to a liver transplant center, and other management measures should also be started in a timely fashion.
In chronic HBV infection, treatment decisions are individualized
In chronic hepatitis B (ie, lasting > 6 months), treatment decisions should be based on the patient's clinical situation and test results. The route and duration of infection (if known), history of previous hepatitis flares, ALT levels, current and previous HBV serologic test results and DNA levels, findings on liver biopsy (if previously done), and clinically suspected cirrhosis are all important to consider when deciding whether antiviral therapy is needed.
Because the HBV DNA level has a major impact on the risk of cirrhosis and hepatocellular carcinoma, it is increasingly the main variable used for treatment decisions. These levels, however, differ according to the clinical stage of chronic HBV infection. 4, 5 
HBV e antigen negativity
Persistent ALT elevation with HBV DNA >2 × 10 3 IU/mL, or Significant liver injury (necroinflammation or fibrosis) on liver biopsy
Compensated cirrhosis
HBV DNA level > 2 × 10 3 IU/mL Consider therapy even with lower HBV DNA levels if ALT is elevated decompensated cirrhosis Any detectable HBV DNA; refer to a liver transplantation center Chronic inactive carriers who have no e an-• tigen, persistently normal ALT levels, and very low or undetectable levels of HBV DNA without evidence of significant liver injury. These patients can be managed by internists by close monitoring for hepatitis flares with serial ALT measurements along with other general management measures.
Antiviral agents for chronic HBV infection
An ideal agent for treating hepatitis B does not exist. Trade-offs are the essence of agent selection.
Interferons, the first drugs shown to be effective against HBV, can in some respects be considered the best available initial choice, especially in patients positive for hepatitis e antigen. Interferons have numerous side effects but, unlike all the other options, they have a well-defined duration of treatment (4-6 months in patients positive for e antigen). The principal goal of this therapy is disappearance of e antigen.
Interferon-based therapy is not recommended in patients with cirrhosis, however, because of the risk of hepatic decompensation associated with interferon-related flares of hepatitis.
4
Nucleoside/nucleotide analogues are easy to use and therefore are usually the first-line therapy. Problems with these agents are that the optimal treatment duration is not known, and that drug resistance can emerge (TABLE 2,   TABLE 3 ).
Of the analogues now available, we recommend tenofovir (Viread) or entecavir. These agents are less likely to result in emergence of resistant strains than the prototypical agent, lamivudine. Three other agents, clevudine, adefovir, and tenofovir with emtricitabine (Truvada), are also available or in late stages of clinical trials.
Although single-agent antiviral therapy may someday be replaced by a multidrug regimen, the data so far are not sufficiently robust to recommend multidrug regimens except possibly in cases of established drug resistance.
Adjunctive management
Vaccinations. All patients with chronic hepatitis B should be vaccinated against hepatitis A if serologic testing indicates they have no immunity to it. Influenza and pneumococcal vaccines are recommended for all patients with chronic liver disease. 6 Test all patients with chronic HBV for hepatitis A, hepatitis C, and possibly HIV and hepatitis D If there is evidence of cirrhosis, esophagogastroduodenoscopy is recommended to screen for esophageal and gastric varices.
Laboratory, radiologic, and histologic findings of prognostic value in HBV-infected patients are outlined in Therefore, patients at risk of HBV infection should be screened for it before starting these therapies. 4 Furthermore, perhaps all patients about to undergo anticancer therapies that include anti-B-cell or anti-T-cell therapies or hematopoietic stem cell transplantation should be screened. 9 Recent data indicate that many oncologists have not been screening for HBV. 10 Hence, more effort is needed to make this important testing routine in this setting.
The initial tests in these patients should be liver chemistry tests, HBV surface antigen, HBV surface antibody, and HBV core antibody. In those who test positive for surface antigen, one should test for e antigen, e antibody, and HBV DNA.
Patients with indications for anti-HBV therapy (TABLE 1) should receive antiviral therapy. Otherwise, those positive for surface anti- 4 Some experts also recommend starting anti-HBV therapy 7 days before the chemotherapy or immunosuppressive therapy and continuing it for 1 year afterward. 10 Those with HBV DNA levels higher than 2 × 10 3 IU/mL should continue HBV therapy until they reach the same treatment end points as for immunocompetent patients as outlined above. 4 Because we have little information on patients who are negative for surface antigen and who have antibodies against surface antigen and core antigen, we cannot make an unequivocal recommendation for anti-HBV therapy in this group. 11 Rather, these patients should be monitored during immunosuppressive treatment, preferably with liver chemistry tests and HBV DNA titers, and antiviral drugs should be given as a deferred therapy upon evidence of HBV reactivation. 9 Few cases of fatal hepatic failure in patients with this serologic pattern receiving rituximab (Rituxan) have been reported. [12] [13] [14] With their small risk of drug resistance and rapid onset of action, entecavir or tenofovir may be the preferred anti-HBV therapy in patients undergoing immunosuppression or chemotherapy, especially in those requiring prolonged immunosuppressive therapy (longer than 12 months). In those requiring shorter courses, lamivudine or telbivudine is a possible alternative. 4 
ouTComES of LIVEr TrANSpLANTATIoN ■ HAVE ImproVEd IN HBV pATIENTS
The early results of liver transplantation for HBV were discouraging because many patients developed rapidly progressive recurrent disease (fibrosing cholestatic hepatitis) and died within 12 to 18 months after the operation. 15 However, patients with HBV are now treated perioperatively with lamivudine or adefovir combined with prolonged administration of hepatitis B immune globulin, and their survival now exceeds that of patients who receive transplants for many other conditions. 16 Like patients with cirrhosis due to other causes, those with HBV-related cirrhosis who have any of the following should be referred for liver transplantation evaluation (TABLE 5) .
A major complication of cirrhosis such as • ascites, variceal bleeding, hepatocellular carcinoma, or hepatic encephalopathy.
prEVENTINg VErTICAL TrANSmISSIoN ■
The major problem in young women with chronic HBV infection is the risk of vertical (mother-to-infant) transmission at
The HBV DNA level has a major impact on the risk of cirrhosis and hepatocellular carcinoma All pregnant women should be tested for HBV early in pregnancy delivery. The risk varies, depending on the viral load and e antigen status of the mother at the time of delivery; if she is positive for e antigen, the risk of HBV infection in the newborn is 70% to 90% by the age of 6 months if the newborn does not receive postexposure immunoprophylaxis; if the mother is positive for surface antigen but negative for e antigen, the risk of chronic infection is less than 10%, even without postexposure immunoprophylaxis. 17 All women should be tested for HBV surface antigen early in pregnancy each time they become pregnant. If a patient tests negative early in pregnancy but continues behaviors that put her at risk of HBV infection (eg, having multiple sexual partners, having had a sex partner positive for surface antigen, using injection drugs, or contracting any sexually transmitted disease), she should be retested at the time of admission to the hospital for delivery. 17 This also includes women who were not screened prenatally and those with clinical hepatitis.
Vaccine and immune globulin for the infant
If the mother is positive for HBV surface antigen, the infant should receive single-antigen HBV vaccine and hepatitis B immune globulin within 12 hours of birth, given at different injection sites. 17 The second dose of vaccine should be given at age 1 to 2 months and the third at age 6 months (but not before age 24 weeks). The response to vaccination should be ascertained by testing for surface antigen and surface antibody after completion of the vaccine series, at age 9 to 18 months.
Maternal HBV infection does not contraindicate breastfeeding, as studies suggest that breastfeeding by a mother positive for surface antigen does not increase the infant's risk of acquiring HBV infection. HBV vaccination, a major achievement in HBV management, has played a big role in reducing the incidence of acute HBV infection, especially in children and adolescents. 20 The currently available vaccines in the United States contain HBV surface antigen derived through recombinant DNA technology from yeast. 21 Two single-antigen vaccines are available in the United States, under the brand names Recombivax HB and Engerix B. Of the three licensed combination vaccines, one (Twinrix) is used in adults, and two (Comvax and Pediarix) are used in infants and young children. Twinrix contains recombinant HBV surface antigens and inactivated hepatitis A virus and it is recommended for people age 18 years and older and at risk of both HBV and hepatitis A infections.
20
Vaccinate all infants All infants should be vaccinated against HBV as part of the recommended childhood immunization schedule. The vaccine is given on a three-dose schedule at birth and again at 1 month and 6 months of age. 16 All children and adolescents under age 19 who have not previously received HBV vaccine should be vaccinated at any age with an appropriate dose and schedule.
16
Vaccinate adults at risk-or who ask for it Hepatitis B vaccination is recommended for all unvaccinated adults at risk of HBV infection and for all adults who ask for it (TABLE 6).
20
TABLE 7 summarizes the adult dosing schedule for HBV vaccines. 20 The vaccines should be given intramuscularly in the deltoid with a 1-to 2-inch needle, depending on the patient's sex and weight. 20 If doses are missed, the series should be resumed as soon as possible; there is no need to restart the series if the time between doses is longer than recommended.
Vaccination is less effective in older people
The three-dose vaccine series given intramuscularly initially, then again at 1 month and 6 months, produces a protective antibody response in approximately 30% to 55% of healthy adults under age 40 after the first dose, 75% after the second dose, and more than 90% after the third dose. 21, 22 After age 40, however, the proportion of persons who have a protective antibody response after three doses declines to less than 90%, and by age 60, protective levels of antibody develop in only 75%. Other factors that lower the response to vaccination are smoking, obesity, genetic factors, and immune suppression. 20 Postvaccination serologic testing for immunity is not necessary after routine vaccination of adults, but it is recommended for patients whose subsequent clinical management depends on knowledge of their immune status, such as health care workers who have contact with patients or blood and are at ongoing risk of injuries with sharp instruments or needlesticks; chronic hemodialysis patients and people infected with HIV or otherwise immunocompromised; and sex partners or needle-sharing partners of people positive for HBV surface antigen. 20 A protective concentration of HBV surface antibody measured 1 to 2 months after completion of the vaccine series is defined as 10 mIU/mL. Further periodic testing to document persistence of protective levels of surface antibody is not indicated.
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If the first series does not 'take'
Patients who do not respond to the primary vaccine series should complete a second three-dose series, with doses at 0, 1, and 6 months. Serologic testing is done 1 to 2 months after finishing the second series.
Patients who do not have protective levels of HBV surface antibody after revaccination by the appropriate schedule in the deltoid muscle (< 5% of those receiving six doses of hepatitis B vaccine) either are primary nonresponders or are infected with HBV. 20 Therefore, they should be tested for HBV surface antigen. If this test is negative, then they should be considered susceptible to HBV infection and should be counseled accordingly.
Contraindications and precautions
HBV vaccination is contraindicated in people with a history of hypersensitivity to baker's yeast or to a previous dose of HBV vaccine. 20 Patients with moderate or severe acute illness at the time the shot is scheduled should wait until they recover before getting HBV vaccine. Pregnancy is not a contraindication. 
